Connect with us

Politics

Canada’s Marijuana Legalization Bill Faces New Challenges

Published

on

Three Canadian Senate committees submitted reports detailing a series of proposed amendments to the government’s marijuana legalization bill this week, threatening to delay and dilute what advocates consider an historic development in cannabis politics.

Though the traditionally conservative Senate passed the bill as written 44-29 in a second reading on March 22, it must now vote on amendments recommended by committees. One such panel is specifically advising the Senate to delay the bill for “as much as a year.”

Here’s what you need to know about each committee report:

Senate Legal And Constitutional Affairs Committee

A majority of Committee on Legal and Constitutional Affairs members proposed several amendments to the bill, including increased penalties for organizations found to be illegally exporting cannabis, limitations on the amount of dried marijuana an individual may possess and a ban on home cultivation.

The committee also unanimously expressed concerns about the risks of implementing marijuana legalization for “vulnerable populations, including youth and people living with mental illness,” as well as “the intrusion of organized crime in the cannabis industry.”

Their report will be considered by the Senate Committee on Social Affairs, Science and Technology, which is scheduled to submit its own report on May 29.

Senate Aboriginal Peoples Committee

The Committee on Aboriginal Peoples submitted a report that called for as long as a year delay on the bill, arguing that Indigenous communities were inadequately consulted about the legalization measure.

In its report, the committee proposed eight amendments. It’s seeking funding for “culturally specific education” about cannabis, the right for Indigenous communities to set their own cannabis taxes and penalties and excise tax revenue for public health and addiction treatment programs, among other things.

“Indigenous peoples are entitled to a say in how the government implements the legalization of cannabis,” Senator Lillian Eva Dyck, who chairs the committee, said in a press release. “They have expressed real concerns to us—the potential for increased harmful effects on indigenous communities on the one hand, and the possibility of losing out on economic opportunities on the other. We must address these issues.”

Senate National Security And Defence Committee

Finally, the Committee on National Security and Defence released a report that called on the government to continue talks and “negotiate an agreement” with the United States about possible consequences for Canadian travelers crossing the border after legalization.

The report cited witness testimony that Canadians may run the risk of facing longer interrogations at the border “and/or inadmissibility for life for a cannabis offense, or for simply admitting previous cannabis use to U.S. customs and border protection officers.”

The report comes about a month after U.S. Attorney General Jeff Sessions, a staunch prohibitionist, met with Conservative Canadian senators to discuss the possible ramifications of the country’s pending legalization of marijuana.

Prime Minister Justin Trudeau Guarded About Prospect of Legalization Delay

Asked about senators’ proposed delay on the implementation of marijuana legalization, Trudeau “left the door open,” The Canadian Press reported Wednesday.

Declining to comment specifically, Trudeau said simply that “legalization is not an event, it’s a process.”

If the Senate accepts any of the committees’ amendments, the bill would then go back to the House of Commons for another vote. Such a delay may impact when legalization would be implemented. And in the event that the House rejects any amendments approved by the Senate, another bicameral volley would again set back the timeline for implementation.

Trudeau’s governing Liberal party initially pushed for legalization to take effect in July.

Sessions Talks Marijuana With Anti-Legalization Canadian Senators

Photo courtesy of Christopher Policarpio.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Los Angeles-based associate editor. His work has also appeared in High Times, VICE and attn.

Politics

Hawaii Lawmakers Approve Marijuana Decriminalization Bill In Joint Committee Hearing

Published

on

Two Hawaii Senate committees approved a bill to decriminalize the possession of small amounts of marijuana in a joint hearing on Tuesday.

The vote comes two weeks after the full House passed the amended legislation, which makes possession of three grams or less of cannabis a civil offense instead of a crime punishable by jail time. As approved by that full chamber, a first the offense was punishable by a $200 fine under the bill, but the Senate committees lowered it to $30 instead.

While the quantity of marijuana is significantly less than in other states have decriminalized, the development was welcomed by reform advocates in the state.

“[W]e embrace the move from criminalization that the bill still represents, and particularly applaud the provisions to dismiss pending charges and expunge convictions related to cannabis offenses,” the reform organization Drug Policy Forum of Hawaii, said in written testimony. “While we support full-scale legalization of adult use cannabis, this bill then also begins to reverse the brutal impact of the decades’ long, needless criminalization of this substance.”

The Senate Committee on Judiciary adopted the House recommendation without objection and advanced the bill. The Senate Committee on Public Safety, Intergovernmental, and Military Affairs didn’t immediately have a quorum during the joint hearing, so that panel didn’t formally take its vote until later in the day.

Besides decriminalizing low-level cannabis possession, the legislation would provide for the expungement of prior convictions cocerning three grams or less.

It would also establish a marijuana evaluation task force to “examine other states’ laws, penalties, and outcomes pertaining to marijuana use, other than marijuana use for medical purposes, and make recommendations on amending marijuana use penalties and outcomes in the State.”

Advocates are cautiously optimistic that Gov. David Ige (D) will sign the bill if it arrives on his desk. While he’s expressed concerns about adult-use legalization, he put his name on decriminalization legislation as a state senator in 2013.

On that note, a separate legalization proposal that advanced further than similar legislation has ever gone in Hawaii after it was approved by a Senate committee last month did not receive consideration in another panel before the deadline to proceed through the legislative process, which effectively killed the bill.

Elsewhere, New Mexico lawmakers sent a more wide-ranging decriminalization bill to the desk of Gov. Michelle Lujan Grisham (D) over the weekend. The pro-legalization governor is expected to sign the legislation.

New Jersey Lawmakers Approve Marijuana Legalization Bill

Photo courtesy of Max Pixel.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

First Congressional Marijuana Vote Of 2019 Officially Scheduled For Next Week

Published

on

A bipartisan bill designed to protect banks that service the marijuana industry from being penalized by federal regulators will get a vote in a key congressional committee next week.

The legislation, which was discussed during the first cannabis-related hearing of the 116th Congress last month, will go before the House Financial Services Committee on Tuesday.

Reps. Ed Perlmutter (D-CO) Denny Heck (D-WA), Steve Stivers (R-OH) and Warren Davidson (R-OH) are the chief sponsors of the Secure and Fair Enforcement (SAFE) Banking Act. It was formally filed earlier this month, and currently has 138 cosponsors—more than a quarter of the House.

“For six years, Congress has failed to act on the issue of cannabis banking, putting thousands of employees, businesses and communities at risk,” Perlmutter said in a statement emailed to Marijuana Moment. “However, the issue is finally receiving the attention it deserves with the first-ever congressional hearing and now a scheduled committee vote.”

‘Among the cosponsors is the chair of the committee herself, Rep. Maxine Waters (D-CA), who spoke about addressing banking issues in the cannabis industry shortly before assuming the position. Judiciary Committee Chairman Jerrold Nadler (D-NY) and Rules Committee Chairman Jim McGovern (D-MA), have also signed onto the legislation—demonstrating its support among powerful Democratic leaders of the House.

All of this sets the stage for a potentially game-changing vote, as Republican leadership during the last Congress consistently blocked marijuana-related bills from even being considered. With Democrats in control and leading lawmakers embracing the legislation, it stands a good chance of heading to the full House and then on to the Senate.

Resolving banking problems for marijuana companies was one of several legislative goals that Rep. Earl Blumenauer (D-OR) outlined in a blueprint to end federal marijuana prohibition he sent to his party’s leaders last year.

“The banking issue is just one aspect of the failed policy of federal marijuana criminalization. In order to truly bring the marijuana industry out of the shadows, actions need to be taken by Congress to amend this, and many others, outdated and discriminatory practices,” Justin Strekal, political director for NORML, said in a statement. “This will certainly not be the last hearing of this Congress to discuss marijuana prohibition and we expect a full hearing on prohibition to be scheduled in the months to come.”

There were several changes made to the banking bill since it was last introduced in the 115th Congress. For example, the legislation clarifies that protections are extended to financial institutions that work with ancillary cannabis business—not just those that directly sell marijuana or marijuana products.

“[P]roceeds from a transaction conducted by a cannabis-related legitimate business shall not be considered as proceeds from an unlawful activity solely because the transaction was conducted by a cannabis-related legitimate business,” the bill states.

It also calls on the Federal Financial Institutions Examination Council to implement “uniform guidance and examination procedures for depository institutions that provide financial services to cannabis-related legitimate businesses.”

There have been widespread calls to tackle the banking problem, including from members of Congress and representatives of cannabis businesses. With this vote, it seems those calls are at least starting to be answered.

Meanwhile, Nadler has signaled that his Judiciary Committee may also take up broader marijuana legislation soon.

“With 97.7 percent of the U.S. population living in a state where voters have legalized some form of adult recreational, medical or limited-medical use of marijuana, congressional inaction is no longer an option,” Perlmutter said. “And with broad, bipartisan support in the House, I look forward to the SAFE Banking Act continuing to move forward in the Financial Services Committee and on the floor of the House.”

This story has been updated to include statements from Perlmutter and NORML.

Congressional Committee Could Take Up Marijuana Reform ‘Fairly Soon,’ Chairman Says

Photo courtesy of Brian Shamblen.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Feds Ramp Up Calls For Research Into Marijuana Treatment For Chronic Pain

Published

on

A federal health agency is seeking the public’s help in identifying studies that explore the potential benefits and harms of using marijuana instead of opioids for chronic pain treatment.

In three separate notices published in the Federal Register on Tuesday, the Agency for Healthcare Research and Quality (AHRQ) said it is in the process of reviewing existing research on chronic pain—specifically alternatives to opioid-based painkillers—and requested “supplemental evidence and data submissions” from the public.

The agency provided guidelines for what exactly it was interested in learning. One notice called for studies on the “comparative effectiveness” of using non-opioid therapies, “including marijuana,” instead of opioids. The studies should explore differences in “outcomes related to pain, function, and quality of life.” The filing also includes a prompt for evidence about utilizing cannabis in tandem with opioids, including how the harms of the prescription pain medications vary for patients who also use marijuana.

In another notice, AHRQ, which is part of the U.S. Department of Health and Human Services, said it wants help completing its review of non-invasive and non-pharmacologic chronic pain treatments such as exercise, mindfulness, acupuncture—and yes, medical marijuana. The request specified that the agency is interested in research on “any formulation” of cannabis.

Finally, a third notice included marijuana in a list of non-opioid pharmacologic treatment options that AHRQ is interested in exploring. The public is encouraged to submit studies and data on the risk of “overdose, misuse, dependence, withdrawals due to adverse events, and serious adverse events” for medical cannabis, as well as more conventional oral and topical treatments.

Altogether, the package of solicitations demonstrates that while marijuana remains a Schedule I drug (meaning the federal government does not recognize it as having medical value), there are federal agencies that are compelled by the prospect that cannabis effectively treats pain without the risks posed by opioids.

And there are any number of studies that AHRQ might want to take into consideration. For example, there are surveys that show patients often use marijuana as a substitute for opioid painkillers and other pharmaceuticals, as well as several comprehensive studies indicating that states with legal cannabis access experience lower opioid overdose rates and have fewer opioid prescriptions compared to non-legal states.

The deadline to submit studies and data for all of the new notices is April 18.

These are the latest in a series of notices that AHRQ and other federal agencies have published in recent months. Last year, the National Center for Complementary and Integrative Health hosted a workshop that specifically addressed barriers to cannabis research while the substance remains federally prohibited.

Anti-Legalization GOP Congressman Slams DEA Over Marijuana Research Blockade

Photo courtesy of Philip Steffan.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Stay Up To The Moment

Marijuana News In Your Inbox


Support Marijuana Moment

Marijuana News In Your Inbox